Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial-Reference-Cited by-同舟云学术

Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial

Published:2023-04-11 Issue:3 Volume:67 Page:301-310
ISSN:0021-5155
Container-title:Japanese Journal of Ophthalmology
language:en
Short-container-title:Jpn J Ophthalmol

Author:

Mori Ryusaburo,Honda Shigeru,Gomi Fumi,Tsujikawa Akitaka,Koizumi Hideki,Ochi Haruka,Ohsawa Shino,Okada Annabelle Ayame,

Funder

F. Hoffmann-La Roche Ltd.

Genentech, Inc

Chugai Pharmaceutical Co.

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10384-023-00985-w.pdf

Reference28 articles.

1. Honda S, Yanagi Y, Koizumi H, Chen Y, Tanaka S, Arimoto M, et al. Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan. Sci Rep. 2021;11:13152.

2. Kume A, Ohshiro T, Sakurada Y, Kikushima W, Yoneyama S, Kashiwagi K. Treatment patterns and health care costs for age-related macular degeneration in Japan: an analysis of national insurance claims data. Ophthalmology. 2016;123:1263–8.

3. Khanna S, Komati R, Eichenbaum DA, Hariprasad I, Ciulla TA, Hariprasad SM. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol. 2019;4:e000398.

4. Takahashi K, Iida T, Ishida S, Crawford B, Sakai Y, Mochizuki A, et al. Effectiveness of current treatments for wet age-related macular degeneration in Japan: a systematic review and pooled data analysis. Clin Ophthalmol. 2022;16:531–40.

5. Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes. Ophthalmol Retina. 2020;4:19–30.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population;Graefe's Archive for Clinical and Experimental Ophthalmology;2024-07-29

2. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes;Graefe's Archive for Clinical and Experimental Ophthalmology;2024-06-07

3. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment;Scientific Reports;2024-04-20

4. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial;Graefe's Archive for Clinical and Experimental Ophthalmology;2024-03-14

5. Short-Term Outcomes of 3 Monthly intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration;Clinical Ophthalmology;2024-02